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Abstract 18 
Background. Cranial electrotherapy stimulation (CES) is a well-tolerated neuromodulation treatment 19 
with demonstrated trial efficacy in anxiety disorders. The aim of the current study was to 20 
demonstrate its clinical and cost effectiveness during and after CES in people with generalised 21 
anxiety disorder (GAD) who had not responded to low intensity psychological treatment in a routine 22 
health service. 23 
Methods. Consecutive sample of eligible patients with GAD waiting for individual cognitive 24 
behaviour therapy (CBT) selected from two publicly funded services in England. They received 60 25 
minutes per day Alpha-Stim CES for 6-12 weeks. Primary outcome was remission on the GAD-7 scale 26 
at 12 and 24 weeks. Cost effectiveness was examined using a cost minimisation model of direct 27 
health costs.  28 
Results. Of 161 patients recruited, 72 (44.7%) and 77 (47.8%) achieved remission on the GAD-7 at 12 29 
and 24 weeks respectively with 122 (75.8%) receiving at least 6 weeks CES. Mean (sd) GAD-7 score at 30 
baseline significantly improved from 15.77 (3.21) to 8.92 (5.42) and 8.99 (6.18) at 12 and 24 weeks 31 
respectively (p<0.001).  80 (49.7%) participants required further individual CBT. CES provided a 32 
saving of £540.88 per patient (95% CI -£327.12, £648.69). 33 
Limitations. Participants were not randomised and there was no control group.  Only 48 (29.9%) 34 
participants completed every assessment.  35 
Conclusion. In patients with generalised anxiety disorder not responding to low intensity 36 
psychological treatment, 6-12 weeks daily Alpha Stim CES may be effective after treatment and 3 37 
months later, thereby reducing the need for individual CBT and saving health costs.  38 
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 58 
Introduction 59 
Generalised anxiety disorder (GAD) is a common and persistent mental disorder with a point or 60 
annual prevalence of 2.1 to 4.4% (Hunt et al, 2002; Grant et al, 2005; Remes et al, 2017; Ruscio et al, 61 
2017). GAD is often present with other mental disorders such as depression, other anxiety disorders, 62 
insomnia and physical illness (Chapman et al 2010; Ruscio et al, 2017), all of which can lead to 63 
considerable health expenditure (Sandelin et al, 2013).  According to the National Institute for 64 
Clinical Excellence (NICE) Guideline for Generalised Anxiety Disorder for England and Wales (NICE, 65 
2011), the first step in the management of GAD is education about the condition and monitoring 66 
delivered in primary care. The second step is low intensity psychological intervention of the person’s 67 
choice, which is provided by the Improving Access to Psychological Treatment service (IAPT) in all 68 
parts of the National Health Service in England (NICE, 2011), usually in the form of facilitated 69 
computerised cognitive behaviour therapy or bibliotherapy (Gyani et al, 2013). While these 70 
approaches are relatively cheap and effective, many people with GAD do not improve and require 71 
additional treatment (Andrews et al, 2018). The third step NICE recommended intervention is either 72 
a high intensity psychological intervention such as individual cognitive behaviour therapy (iCBT), also 73 
delivered by IAPT services and relatively expensive, or drug treatment, initially with selective 74 
serotonin reuptake inhibitor antidepressants but if these are ineffective then more expensive drugs 75 
such as pregabalin are used. There can be a substantial delay before iCBT can be offered (Sandelin et 76 
al, 2013). 77 
 78 
Cranial electrotherapy stimulation (CES) was first utilised to induce sleep and relaxation using bursts 79 
of small electric currents applied to the head in the 1900s (Guleyupoglu et al, 2013). Improvements 80 
have taken place in electrode placement, use of battery driven devices and understanding of dose, 81 
frequency of treatment and waveform that is required to improve anxiety symptoms. Single courses 82 
of CES are associated with changes in electroencephalography (EEG) from delta (0-3.5Hz) and beta 83 
(12.5-30Hz) frequencies to more relaxing and alerting alpha frequencies (8-12 Hz) (Kennerly, 2004). 84 
Cortical and subcortical brain activation on fMRI have been demonstrated  in people with high levels 85 
of anxiety (Feusner et al, 2012) and increases in plasma beta endorphins, adrenocorticotrophic 86 
hormone and cortisol (Liss and Liss, 1996; Shealy et al, 1998) after a single 20 minute CES treatment.   87 
 88 
A recently published systematic review funded by the United States Department of Veteran Affairs 89 
identified five randomised controlled trials (RCTs) with 198 participants for anxiety disorders 90 
comparing active CES to sham CES (Shekelle et al, 2018). It concluded that there was low quality 91 
evidence of the effectiveness of CES for anxiety and depression symptoms in people with anxiety 92 
disorders at the end of treatment as well as evidence that CES does not cause serious side effects. A 93 
randomised controlled trial in 115 volunteers with a primary anxiety disorder showed the 94 
effectiveness of 5 weeks of active CES versus sham CES on anxiety and depression symptoms at the 95 
end of treatment (Barclay and Barclay, 2014). However, there have been no studies of the 96 
maintenance of clinical improvement or cost effectiveness of CES in treatment seeking patients with 97 
GAD who had not responded to second-line treatment as recommended by NICE (2011). Therefore 98 
we examined the clinical and cost effectiveness of 6-12 weeks CES treatment for treatment seeking 99 
patients with GAD who had not responded to facilitated computerised cognitive behaviour therapy 100 
or bibliotherapy over 24 weeks. These patients were all waiting for iCBT for GAD. 101 
 102 
There are four aims to the current study to determine: 103 
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1. The proportion of patients treated with CES in IAPT services who reach the clinical threshold 104 
for remission (GAD-7 score of 7 or less; Spitzer et al, 2016), reliable improvement and 105 
recovery after treatment at 12 weeks. 106 
2. The proportion of patients treated with CES in IAPT services who maintain the clinical 107 
threshold for remission (GAD-7 score of 7 or less), reliable improvement and recovery at 24 108 
weeks. 109 
3. If there are significant changes over 24 weeks in generalised anxiety, depression, insomnia, 110 
social adjustment and quality of life. 111 
4. If the cost of CES offsets the cost of psychological treatment and other treatment over 24 112 
weeks. 113 
 114 
Method 115 
Design. This is a study in routine care carried out after efficacy has been established against sham 116 
treatment in a meta-analysis of RCTs (Shekelle et al, 2018) to establish the effectiveness and costs in 117 
routine care settings as outlined by the United Kingdom Medical Research Council Complex 118 
Intervention Framework (2000) and the National Institute for Health and Care Excellence (2018). An 119 
open consecutive patient cohort design with 24 week follow up in National Health Service (NHS) 120 
mental health treatment settings in England was employed where all participants were offered 121 
Alpha-Stim cranial electrotherapy stimulation (CES) for 6-12 weeks if they had not reached remission 122 
with therapist or full guided self-help and were waiting to receive individual cognitive behaviour 123 
therapy (iCBT).  124 
Setting. Two NHS Improving Access to Psychological Treatment (IAPT) services in the same county in 125 
England covering a more affluent urban and rural area and a less affluent inner city area. The 126 
services were run by two different NHS organisations. All data and treatment were delivered by staff 127 
who were independent of the company who makes Alpha Stim CES.  Ethical approval for the study 128 
was granted by the Nottingham 2 NRES committee (IRAS206555). 129 
Inclusion/exclusion criteria: 130 
1. A score of 8 or more on GAD-7 scale, a 7-item self-rated measure of symptoms of 131 
generalised anxiety disorder (Spitzer et al, 2016), because nationally IAPT services determined that 132 
further treatment should be offered after full or guided computerised self-management or 133 
bibliotherapy if a person scores above the threshold for remission i.e. a total score of 8 or more. 134 
2. A clinical diagnosis of generalised anxiety disorder alone or in combination with a comorbid 135 
depression or other anxiety disorder e.g. obsessive compulsive disorder or physical health morbidity. 136 
Excluded was a diagnosis of any other mental disorder e.g. substance use disorder, eating disorder, 137 
bipolar disorder, non-affective psychosis. In keeping with an implementation study the diagnostic 138 
information used for the inclusion and exclusion criteria were made on clinical grounds without 139 
using any standardised psychiatric interviews by clinically qualified mental health professionals 140 
independently of the research team.  141 
3. On waiting list for individual CBT (high intensity psychological intervention). 142 
4. Does not require urgent clinical care.  143 
5. If female not known to be pregnant. 144 
6. Implantation with a pace maker or an implantable cardioverter device (ICD) are exclusions. 145 
6. Gives informed written and oral consent to the study. 146 
7. Agrees to return Alpha-Stim equipment at the end of the study. 147 
5 
 
Being on medication did not lead to exclusion. 148 
Outcome measures: 149 
These are standard clinical outcome measure employed routinely by the NHS IAPT services with the 150 
addition of measures of insomnia, quality of life and an economic interview to assess health costs. 151 
They were collected face to face at baseline. Clinical outcome and quality of life measure were 152 
collected at four, six, eight, 12 and 24 weeks by e-mail, telephone or post according to participant 153 
preference.  A second economic interview was conducted by telephone or Skype at six months 154 
according to participant preference. All participants who completed the economic interview were 155 
given a £10 gift voucher in recognition of the time given to completing the research outcome 156 
assessments.  157 
 158 
Primary outcome measure:  159 
The primary outcome is the proportion of participants who reach remission (7 points or less) at 12 160 
and 24 weeks on the GAD-7 since IAPT services are paid according to the proportion of patients who 161 
reach this threshold after treatment in their service (Richards and Borglin, 2011). Other key 162 
outcomes are the proportion of cases who meet a clinically important (“reliable improvement”) 5  163 
point improvement on the GAD-7 at 12 and 24 weeks (Richards and Borglin, 2011), the proportion 164 
who meet criteria for recovery (GAD-7 score of 7 or less and also exhibiting a 5 point drop in GAD-7 165 
score) at 12 and 24 weeks (Richards and Borglin, 2011), and the effect size of the change in GAD-7 166 
score over 12-24 weeks. A clinically important deterioration is an increase in GAD-7 score of 5 points 167 
at 12 and 24 weeks (Richards and Borglin, 2011).    168 
Secondary outcome measures:  169 
1. Personal Health Questionnaire, 9-item (PHQ-9; Kroenke et al, 2001), a 9-item self-rated 170 
measure of the severity of depression symptoms. Remission is a total score of 9 or less at 12 or 24 171 
weeks in those who had scored 10 or more at baseline, reliable improvement is a drop of 6 points or 172 
more, and recovery is a score of 9 or less and a 6 point drop at 12 and 24 weeks (Richards and 173 
Borglin, 2011). We also examined the effect size of the change in PHQ-9 score symptoms from 174 
baseline to 12 and 24 weeks. 175 
2. Athens Insomnia Scale (AIS; Soldatos et al, 2000).  This scale has 8 items with a maximum 176 
score of 24. A score of 6 indicates a possible sleep problem and 4 indicates recovery (Soldatos et al, 177 
2003). Therefore remission is defined as the proportion of people who score a total of 4 or less at 12 178 
and 24 weeks. No data exists on reliable improvement so a drop of 50% in baseline score by 12 and 179 
24 weeks was used. Recovery is the proportion of people who showed a drop of 50% in baseline 180 
score and scored 4 or less at 12 and 24 weeks. We also examined the effect size of the change in 181 
insomnia symptoms from baseline to 12 and 24 weeks. 182 
3. Work and Social Adjustment Scale (WASA; Mundt et al, 2002), an 8-item self-rated measure 183 
of work and social function. A total score of 20 or more indicates considerable impairment in 184 
function (Mundt et al, 2002). A return to normal function requires a total score of 10 or less and 185 
functional recovery requires a total score of 11 or more at baseline with a drop to 10 points or below 186 
by 12 and 24 weeks (Mundt et al, 2002). We also examined the effect size of the change in WASA 187 
score from baseline to 12 and 24 weeks. 188 
4. EQ5D-5L (EuroQol, van Hout et al, 2012), a 6- item self-rated measure of health utility and 189 
quality of life. We examined the effect size of the change in EQ5D-5L from baseline to 12 and 24 190 
weeks. 191 
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 192 
Economic interview: 193 
We used the Client Service Receipt Interview (CSRI; Beecham and Knapp, 1992) adapted for use in 194 
studies of anxiety disorders in primary care and community settings. It was completed at baseline 195 
and 24 weeks. 196 
 197 
Procedure. 198 
Consecutive treatment seeking patients who received low intensity IAPT interventions (therapist 199 
guided self-management on a computerised CBT programme or bibliotherapy for GAD) but had not 200 
reached a total score of 8 or more, were unlikely to meet any exclusion criteria for the study, and 201 
were willing to be placed on a waiting list for iCBT, were identified from IAPT service records.  IAPT 202 
staff contacted a potential participant to seek permission for their contact details to be passed to 203 
the study team who checked their eligibility over the phone. A face to face meeting was arranged 204 
with a member of the study team who checked the inclusion/exclusion criteria and sought written 205 
informed consent. If the participant consented study staff showed the participants how to use the 206 
Alpha-Stim CES device, outlined how to obtain support while using it, and negotiated the return of 207 
the CES device at the end of 6-12 weeks treatment.  Women of child-bearing potential completed a 208 
urine pregnancy dipstick human chorionic gonadotropin test.   209 
Alpha-Stim AID is a CE marked medical device which is marketed for the alleviation of psychological 210 
conditions including anxiety, insomnia and depression, through using cranial electrotherapy 211 
stimulations (CES) which are tiny electric currents applied through ear clips worn for 60 minutes per 212 
day. The treatment provided by the device is therefore non-invasive, non-pharmacological, and can 213 
be used as adjunctive treatment to drug or psychological treatment or a treatment on its own. All 214 
participants were offered 60 minutes per day of alpha-stim CES treatment at a current of one 215 
hundred micro amps per day 7 days per week for 6 consecutive weeks. The 60 minutes session starts 216 
when the ear clips are attached and stops automatically when the hour is finished. The device was 217 
not locked because it would not be in usual clinical practice. The device did not automatically record 218 
adherence to treatment.  Participants could choose to continue with the same CES treatment for a 219 
further 6 weeks, thereby completing 12 weeks CES treatment in total.   At the end of 12 weeks the 220 
participants could not receive any further CES treatment. Since this was a naturalistic study, 221 
decisions concerning if and when iCBT might be received by the participant were made by IAPT staff 222 
with the participants; the study team did not influence this decision. If participants started iCBT 223 
during the 6-12 weeks of CES, they could continue with CES while receiving iCBT at the same time. 224 
Similarly general practitioners could independently decide to place the patient on medication for 225 
GAD at the same time as participants continued to receive CES. A summary of the procedures of the 226 
study is shown in Table 1; as well as outcome measures, adherence to CES and side-effects were 227 
recorded at each study visit. 228 
Sample size.  229 
A meta-analysis of 5 CES RCTs estimates an effect size of at least 0.60 (Shekelle et al, 2018). On this 230 
basis remission might be expected in 26.5% patients with GAD receiving alpha stim CES in IAPT 231 
settings. The aim was to recruit a sample with at least 25 participants achieving remission after alpha 232 
stim CES at 12 weeks and followed up at 24 weeks; a sample of 160 would be required assuming 40% 233 
loss to follow up by 24 weeks.  234 
Statistical analyses. 235 
Prior to statistical analyses, data screening was conducted to evaluate the tenability of assumptions 236 
specific to the general linear model (GLM). These assumptions included normally distributed outcome 237 
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variables, independence of observations for different subjects, and homogeneity of covariance 238 
matrices within subjects across repeated measurements. The assumptions of the GLM were tenable 239 
except for homogeneity of covariance within subjects on their measurements over time. The 240 
Greenhouse-Geiser adjustment was applied to F-statistics and degrees of freedom when violations 241 
appeared. After data screening, analyses proceeded using a within-subjects repeated measures 242 
analysis of variance (RM ANOVA) for the primary outcome and secondary outcome variables. 243 
Additionally, regarding aims 1 and 2, descriptive analyses were conducted to determine remission, 244 
reliably improvement and recovery.   245 
To answer our research aim 3, we used a within-subjects univariate repeated measures analysis of 246 
variance (RM ANOVA). Separate univariate RM ANOVAs were conducted for each outcome variable in 247 
two distinct phases. The first set of analyses proceeded using data from the empirical sample. The 248 
second set of RM ANOVA analyses included an intention-to-treat (ITT) analysis strategy using a full 249 
complement of scores on each outcome variable. The following section includes information specific 250 
to the ITT analytic approach.  251 
Intention-to-treat (ITT) analysis avoids overoptimistic estimates of the efficiency of an intervention 252 
resulting from the removal of non-compliers by accepting that noncompliance and protocol deviations 253 
are likely to occur in clinical practice.  Intention-to-treat analyses was applied including all patients as 254 
they were assigned at baseline, regardless of their adherence to treatment, the treatment they 255 
received or any subsequent withdrawal from the study (Fisher, 1990).  To evaluate the type or pattern 256 
of missing scores for each outcome measure, the missing completely at random (MCAR) test was 257 
employed (Little and Rubin, 2002; Enders, 2010). Once the data was determined to adhere to MCAR 258 
(i.e. p >.05), replacement of scores proceeded using model-based full information maximum likelihood 259 
(.FIML) estimation. 260 
 261 
Health economics 262 
In order to determine the cost impact of introducing CES into the pathway as a second-line 263 
treatment instead of or prior to individual CBT (iCBT), a cost minimisation analysis was undertaken 264 
using a health economic (HE) model decision tree (see Figure 1). In both branches of the HE model 265 
the patient population was non-responders to low-intensity guided or full computerised self-help or 266 
bibliotherapy given as the first-line treatment. The decision tree was populated with the 267 
probabilities of response to second line CES treatment from the study versus second-line iCBT with 268 
the remission rate of 54.2% from Gyani et al (2013) which is the average remission rate between 269 
guided and full self-help groups in that study. In addition, the same probability of outcome from 270 
subsequent iCBT sessions given to non-responders in both arms was modelled as in the current 271 
pathway (treatment as usual) such that for non-responders to second-line iCBT a further course of 272 
the same number of iCBT sessions would follow. For non-responders to second-line CES up to two 273 
further courses of iCBT were included in the decision tree. In all cases successful response was 274 
measured by the achievement of the GAD-7 threshold of remission as used in the IAPT programme 275 
(Richards and Borglin, 2011). Neither a cost-utility analysis nor a cost-consequences analysis was 276 
employed because the study did not have a comparator for outcomes although EQ-5D results are 277 
reported here separately for Alpha-stim CES treatment. 278 
The hypothesis tested in the HE model was that adding CES as a second-line treatment in the 279 
pathway will eliminate, for the proportion of patients who respond to CES, the need for the more 280 
expensive iCBT leading to cost savings. Although not included in the model, it would also potentially 281 
reduce waiting times for those patients who would still progress to iCBT since early response to 282 
available CES therapy promises to free up therapist resource for iCBT as well as potentially the 283 
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number of iCBT sessions each participant would need after receiving CES.  The HE model used a 6-284 
month time horizon, reflecting the expected duration of GAD response (NICE, 2011) and including 285 
the time period for consecutive treatments of CES and/or iCBT.  Given this short time horizon, costs 286 
were not discounted.  287 
The modelling was undertaken from the United Kingdom NHS payer perspective with prices uplifted 288 
using the most recent national annually published resource, the PSSRU Unit Costs of Health and 289 
Social Care 2017 (Curtis and Burns, 2017) which gave compounded ratios for an uplift up to 2016. 290 
Costs were derived for CBT from Radhakrishnan et al (2013) for 60 or 90 minutes of iCBT (£98.59 or £ 291 
176.97 per session) uplifted from 2010 to 2016 prices using the appropriate ratio of 1.09 yielding £ 292 
£110.96 and £199.17 respectively. Overall treatment costs were computed for 8 sessions of 60 293 
minutes iCBT, as in the ‘standard of care’ model, yielding a total cost of £887.68. For comparison, the 294 
model was also constructed with alternative choices of two additional more expensive iCBT regimes: 295 
the ‘Clark and Wells model’ with 14 sessions of 90 minutes sessions of iCBT, costing £2788.43 in total 296 
and the ‘Heimberg model’ with one session of 90 minute iCBT followed by 15 sessions of 60 minutes 297 
iCBT, costing £1863.57 in total (NICE, 2013). 298 
Alpha-stim CES cost per treatment was a manufacturer estimate from the unit cost of the device of 299 
£450.00 (excluding valued added tax) with a utilisation of 15 patients over an average product 300 
lifetime of 3 years (based on a 10 week sole use per patient). It allowed for losses with respect to the 301 
quoted 5 year warranty that was estimated to reduce average product lifetime by 2 years. A 302 
Additional therapist time, postage and consumables was estimated at £40, yielding £70 per 303 
treatment. 304 
A probabilistic sensitivity analysis (PSA) was undertaken on cost of treatment, probability of 305 
response and utilisation of response with parameters as shown in Table 2 (York Health Economics 306 
Consortium, 2016). In addition a one-way deterministic threshold analysis was performed on cost to 307 
find the price at which the intervention would no longer be cost saving.  Probabilistic sensitivity 308 
analysis (PSA) is a technique used in economic modelling that allows the quantification of the level of 309 
confidence in the output parameters of the analysis, in relation to the uncertainty in the model 310 
inputs. In the probabilistic analysis, the parameters’ value from clinical trials, observational studies 311 
or in some cases expert opinion are represented as distributions around their deterministic value. A 312 
set of input parameter values is drawn by random sampling from each distribution, and the model 313 
generates outputs (cost and health outcome), which are stored. This is repeated in many iterations 314 
of the model (typically 1,000 to 10,000), resulting in a distribution of outputs that can be graphed on 315 
the cost-effectiveness plane, and analysed. 316 
 317 
Results 318 
Figure 2 shows the flow of participants through the study. Only 22% of potentially eligible patients 319 
agreed to take in the study. All 161 participants started CES treatment and 112 (69.6%) completed at 320 
least 6 weeks treatment. Of the 49 (30.4%) participants who withdrew from treatment by 12 weeks, 321 
nine (5.6%) could not find the time to complete the treatment, four (2.5%) withdrew because of no 322 
improvement, four (2.5%) withdrew because of side effects (two with headaches and insomnia, one 323 
with nausea and one with a strange feeling after use), two (1.2%) withdrew because they felt better, 324 
and 30 (18.6%) gave no reason. Of the 161 participants, 80 (49.7%) had iCBT. Eighty-one (50.3%) 325 
completed follow ups to 12 weeks and 72 (44.7%) to 24 weeks. 326 
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Table 2 shows that participants were drawn from a broad range of ages and nearly three quarters 327 
were female. The overwhelming majority were white British, most had at least high school 328 
education, married and were in employment. However, the mean baseline scores were in the severe 329 
range for GAD (Spitzer et al, 2001), moderately severe range for depression (Kroenke et al, 1999), 330 
showed significant sleep difficulties (Soldatos et al, 2004), substantial functional impairment (Mundt 331 
et al, 2002), and low health utility comparable to scores for out-patients with a broad range of 332 
physical and mental disorders (van Hout et al, 2012).  333 
Table 3 shows the primary outcome. By 12 weeks, 72 (44.7%) participants achieved remission and 334 
recovery on the GAD-7 at 12 weeks and 76 (47.2%) at 24 weeks. The proportions of participants 335 
achieving reliable improvement on the GAD-7 were 102 (63.4%) and 105 (65.2%) at 12 and 24 weeks 336 
respectively. No patient showed reliable deterioration at 12 or 24 weeks.  There was a drop in GAD-7 337 
score from mean (sd) 15.77 (3.21) to 8.92 (5.42) by 12 weeks and this is maintained to 8.99 (6.18) at 338 
24 weeks, a mild degree of GAD-7 symptoms by 12 and 24 weeks. The within-subjects effects is 339 
statistically significant (F=72.02, df1=3.7/df2=563.74, p<0.001) and the effect size is medium (partial 340 
eta square=0.31). The vast majority of the drop in GAD-7 is experienced in the first 6 weeks and 341 
there is no statistically significant difference between week 6 and any subsequent time point up to 342 
week 24. The same pattern is seen in 48 participants with assessments at every time point except 343 
the effect size of the within subjects treatment effect was large rather than medium (Appendix Table 344 
1).  Of the 81 participants who only received CES, 49 (60.3%) achieved remission on the GAD-7 at 12 345 
weeks and 53 (65.4%) achieved remission on the GAD-7 at 24 weeks. Of the 25 participants who 346 
received both CES and iCBT, 17 (68%) achieved remission and recovery on the GAD-7 and 23 (92%) 347 
achieved reliable improvement at 12 and 24 weeks.  348 
Table 3 shows that the effects on the PHQ-9 were similar in relation to the GAD-7 although a lower 349 
proportion achieved a reliable improvement at 12 and 24 weeks. The within subjects effect was 350 
significant (F=42.89, df1=3.9/df=559.01, p<0.001) with the mean PHQ-9 score dropping from the 351 
moderately severe range to the mild range but the effect size was small (partial Eta square=0.21). 352 
There was some worsening of depression symptoms by week 24 and the fall in PHQ-9 score was only 353 
significant between baseline and 12 weeks but not 24 weeks. Only around a quarter of participants 354 
achieved remission on the Athens Insomnia Scale at 12 and 24 weeks. There was a statistically 355 
significant within-subjects drop in insomnia over the 24 period (F=42.69, df1=5.0/df=542.9, p<0.001) 356 
and the effect size was medium (partial Eta square=0.21).  357 
Table 3 also demonstrates that just over a quarter of participants made a functional recovery on the 358 
WASA at 12 and 24 weeks with CES. Figure 2 and Table 3 show that there is a significant within-359 
subjects effect of Alpha-Stim CES over the 24 weeks (F=17.35, df1=3.5/df=557.45, p<0.001) but the 360 
effect size is small (partial Eta square=0.10). The effects of Alpha-Stim CES on the EQ-5D-5L were 361 
very similar to the WASA with a significant within subjects effect over 24 weeks (F=13.94, 362 
df1=4.1/df2=651.3, p<0.0001) but the effect size is also small (partial Eta square=0.08).  363 
The results of the health economics decision tree model populated with the costs and probabilities 364 
for the 8 session standard care model of CBT yielded the results as shown in Table 4. The costs and 365 
responses are presented for a cohort of 1000 patients. CES provided a saving of -£540,878 (95% CI [-366 
£648,692, -£327,117]) and the number of responses to treatment were increased by 187.56 per 367 
1000 (95% CI [141.03, 227.82]). Using the “Clark and Wells model” of iCBT as comparator, CES 368 
provided a saving of -£1,637,410 (95% CIs -£1,914,463, -£1,175,437]) and the number of responses 369 
to treatment were increased by 187.56 per 1000 (95% CIs [141.58, 226.12]). With the Heimberg 370 
Model as a comparator, CES provided a saving of -£1,212,463 (95% CIs -£1,429,369, -£843,394]) and 371 
10 
 
the number of responses to treatment were increased by 187.56 per 1000 (95% CIs [140.79., 372 
227.71]). Cost-outcome scatterplots for each model are shown in the Appendix.  373 
 374 
 375 
Discussion 376 
This study shows that in moderate to severe treatment seeking patients with GAD, nearly 45 per 377 
cent of patients achieved remission and 63 per cent reliable improvement in their self-rated anxiety 378 
symptoms with Alpha-Stim CES treatment.  These improvements were maintained for a further 12 379 
weeks after CES was completed whether or not patients received iCBT in addition. Most of the 380 
improvement with CES was seen in the first 4 weeks.  It had a moderate effect size. Remission rates 381 
are lower than  reported for iCBT in routine IAPT services in the UK (Radhakrishnan et al, 2013); 382 
however our sample had substantially higher scores than routinely reported for IAPT services 383 
(Radhakrishnan et al, 2013; NHS Digital, 2018). . Approximately 50 per cent of patients on the 384 
waiting list for iCBT received iCBT, thereby enabling the NHS IAPT services to treat other patients on 385 
the waiting list for iCBT. The mean severity of GAD-7 symptoms decreased from severe to mild and 386 
below case threshold over 12 weeks and remained at that level for 24 weeks. There were similar 387 
drops in depression symptoms and insomnia symptoms as well as improvements in function and 388 
quality of life although all of these effects were smaller with some slippage between 12 and 24 389 
weeks. Although there was a significant drop in depression symptoms between baseline and 12 390 
weeks, it was not significant at 24 weeks indicating that the effects of CES on depression symptoms 391 
had started to wane by 24 weeks. Overall a quarter of patients receiving CES regained a functional 392 
recovery. Alpha-Stim CES was well tolerated with only six (4%) patients stopping it because of side-393 
effects and four (3%) because they were not making any progress. Compared to a standard course of 394 
iCBT (eight sessions or longer), Alpha-stim CES reduced costs of care by £540 or more per patient 395 
and it was also cost effective. 396 
The strengths of the study were that clinical and cost effectiveness was examined in a consecutive 397 
large sample of treatment seeking patients in universally available publicly funded services provided 398 
by the state irrespective of the ability to pay or health insurance. Inclusion criteria were set to reflect 399 
the criteria used by IAPT services to offer individual CBT. This criteria was set at 8 or more on the 400 
GAD-7 reflecting the upper end of mild severity compared to the usual clinical thresholds for mild , 401 
moderate and severe anxiety of 5, 10 and 15 on the GAD-7 (Spitzer et al, 2006). However 95 per cent 402 
of the sample had moderate or severe symptoms of GAD at baseline, well above the minimum 403 
threshold for entry to the study and the national NHS IAPT criteria for remission. They had already 404 
failed to improve with facilitated bibliography or computerised psychological treatment for GAD, so 405 
spontaneous improvement was unlikely. Placebo responses are less  frequent in research 406 
participants with less severe anxiety or depression and in those who have not responded to previous 407 
active treatment for their condition (Stein et al, 2006; Weimer et al, 2015). Therefore the study 408 
shows the effectiveness of CES in a clinical treatment seeking sample of patients with moderate to 409 
severe treatment resistant generalised anxiety disorder.  410 
There are important limitations of the study. There was no control group and the study was not a 411 
randomised controlled trial. However meta-analysis of previous RCTs of active CES versus sham CES 412 
already provides evidence that CES is effective in treating anxiety and depression symptoms 413 
(Shekelle et al, 2018).  The United Kingdom Medical Research Council (2000) and National Institute 414 
for Health and Care Excellence (2018) recommend that implementation studies are completed in 415 
routine treatment settings to check that the efficacy seen in RCTs is translated into routine clinical 416 
practice settings. This study was therefore designed to meet this requirement, to examine if 417 
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effectiveness is maintained after CES treatment completion, and if there were any cost savings from 418 
CES treatment. Such studies do not necessarily utilise control groups; they must enrol treatment 419 
seeking patients studied under routine care delivery. Alpha-Stim CES was more effective at achieving 420 
remission than we expected from the effect size in a meta-analysis of RCTs (Shekelle et al, 2018) 421 
with 44.7% patients achieving remission, comparable to iCBT in routine treatment settings, rather 422 
than 26.5% patients as we had planned.  423 
The sample recruited only 22 per cent of those eligible to take part in the study. However, the offer 424 
to take part in this research and to receive this treatment came through cold calling by the clinical 425 
team through letter, e-mail or telephone call. If participants were prepared for the possibility of 426 
receiving CES by the IAPT services then uptake of CES might be higher.  A strength of cold calling and 427 
lack of research team contact is that placebo responses to CES may have been low because of 428 
infrequent contact of the research team so that the effectiveness of CES in the study was not 429 
inflated compared to clinical practice.  430 
Another limitation of the study was that the sample lacked ethnic diversity.  The sample was drawn 431 
from all ages although there were greater proportions of younger and middle aged participants in 432 
the study, reflecting the composition of age groups in routine IAPT NHS services. As expected the 433 
vast majority of patients with GAD were female. There was a broad representation of education, 434 
marital status and employment status reflecting the age composition of the sample.  435 
There was a high degree of attrition of the study to follow up with the loss of 55.2% by 24 weeks 436 
despite financial incentive to provide data as opposed to 40% that we had anticipated. The study 437 
was adequately powered because CES was more effective than we had expected. The results are 438 
similar between the ITT sample with imputed results and those completing all follow up assessments 439 
suggesting that the conclusions drawn from the whole sample using imputation are probably safe to 440 
make. We also only have a limited amount of information on the reasons that participants withdrew 441 
from CES or follow up. The most common reason given for withdrawal from CES is not being able to 442 
find the time to use CES for 60 minutes per day. The CES device was also not locked so some 443 
participants may have used a higher current than we instructed them to and got adverse effects that 444 
they chose not to report. We have no evidence that anyone did this. Almost as many dropped out of 445 
CES because it had worked as those who stopped because it did not. A limitation of the health 446 
economics analysis is that we did not consider the possibility that CES  might have reduced the delay 447 
in receiving iCBT by freeing up capacity in other CBT therapists or that those patients who received 448 
both CES and iCBT might have had fewer iCBT sessions. Therefore cost savings from CES may be 449 
underestimated in treatment settings offering iCBT for GAD.  450 
We did not personalise CES to each individual. It is possible that different waveforms of current, 451 
stimulus intensity and stimulation location might have been more efficacious for some participants 452 
(Guleyupoglu et al, 2013). Some participants may have tolerated 5 days of treatment with CES per 453 
week better than 7 days per week with higher completion rates of 6-12 weeks CES treatment. 454 
As well as improvements in anxiety, there were improvements in depression and insomnia, two 455 
other potential indications for CES. Although the results are encouraging, further research is needed 456 
in patients with primary depression and primary insomnia disorders. There were also high remission, 457 
recovery and reliable improvement rates in GAD-7 score when participants received both iCBT and 458 
CES in the first 12 weeks. Research might explore if higher and more sustained rates of remission are 459 
in generalised anxiety disorder in trials of iCBT plus active CES versus iCBT plus sham CES. 460 
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In conclusion, we provide evidence that CES may be clinically effective and cost reducing during 461 
administration and for three months afterwards in routine treatment settings offering psychological 462 
treatments for moderate to severe GAD. CES improves the efficiency of these services, a critical issue 463 
because of the shortage and high turnover of psychological treatment staff, allowing them to reach 464 
their targets for remission with fewer highly skilled staff. As a result, it is also cost saving to such 465 
services even when a range of different assumptions are made about the delivery of psychological 466 
treatment.  467 
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Table 1. Procedure and assessments in the study (n=161) 609 
ASSESSMENT VISIT 1 
BASELINE 
VISIT 2 
WEEK 4 
VISIT 3 
WEEK 6 
VISIT 4 
WEEK 8 
VISIT 5 
WEEK 12 
VISIT 6 
WEEK 24 
CONSENT X      
TRAINING TO 
USE CES 
X      
PREGNANCY 
TEST 
X (*)      
GAD-7 X X X X X X 
EQ-5D-5L X X X X X X 
CSRI X    X X 
WASA X X X X X X 
PHQ-9 X X X X X X 
AIS X X X X X X 
ALPHA-STIM 
CES  
Ongoing Ongoing Ongoing 
(**) 
Ongoing 
(**) 
Ongoing 
(**) 
 
ADHERENCE     X X X (**) X (**)  
ADVERSE 
EVENTS 
 X X X (**) X (**)  
 610 
(*) If a female of child-bearing potential 611 
(**) If continuing with Alpha-Stim AID CES treatment between week 6 – week 12. 612 
  613 
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Figure 1. Decision Tree model for comparison of Alpha-stim CES pathway with individual cognitive 614 
behaviour therapy (iCBT) treatment as usual. 615 
 616 
 617 
  618 
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Figure 2: Flow into Study 619 
  620 
Assessed for eligibility (n=743): 
met study inclusion criteria on 
IAPT database 
Excluded (n=582) 
   Not meeting inclusion criteria (n= 1) 
   Declined to participate (n=581) 
 
Analysed (n=161,100%) 
 
4 weeks: (n=120, 75%). Lost to follow-up (n=41, 25%). Stopped Alpha-Stim CES (n=25, 15.5%), 
Received iCBT (n=43, 26.7%) 
Allocated to and received intervention (n=161) 
 
Allocation 
Analysis 
Follow-Up 
Entered (n=161) 
Enrolment 
6 weeks: (n=94, 58.3%). Lost to follow up (n=67, 41.7%). Stopped Alpha-Stim CES (n=39, 24.2%). 
Received iCBT (n=47, 29.2%) 
8 weeks: (n=89, 55.3%). Lost to follow up (n=72, 44.7%). Stopped Alpha-Stim CES (n=42, 26.1%). 
Received iCBT (n=56, 34.8%) 
12 weeks: (n=81, 50.3%). Lost to follow up (n=80, 49.7%). Stopped Alpha-Stim CES (n=49, 30.4%). 
Received iCBT (n=80, 49.7%) 
24 weeks: (n=72, 44.7%). Lost to follow up (n=89, 55.2%). Received iCBT (n=80, 49.7%) 
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Table 2. Baseline characteristics of participants (n=161). 621 
Variable Mean (sd) or n(%) 
Age, years 38.00 (14.2) (min=18, max=76) 
Gender, female 118 (73.3%) 
Ethnicity, white British 153 (95.0%) 
Marital status: Married or cohabiting 
                           Single 
                           Divorced 
                           Widowed 
 95 (59.0%) 
 50 (31.1%) 
 12 (7.5%) 
   4 (2.5%) 
Education: No qualifications 
                    GCSE ( left school at 16 years) 
   A level or other non-degree higher qualification 
                    Degree  
   5 (3.1%) 
 39 (24.2%) 
 67 (41.6%) 
 50 (31.1%) 
Employment: Employed 
                         Unemployed 
                         Retired 
                         Student 
                         Homemaker 
106 (65.8%) 
 33 (20.5%) 
 11 (6.8%) 
   7 (4.3%) 
   4 (2.5%) 
GAD-7 15.77 (3.21) 
PHQ-9 16.07 (4.94) 
Athens Insomnia Scale 12.91 (4.82) 
WASA 20.81 (7.74) 
EQ-5D-5L 51.61 (19.0) 
 622 
  623 
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Table 3:  Intention to treat analysis of remission, reliable improvement, recovery and mean (sd) 624 
continuous outcomes with Alpha-stim CES at 12 and 24 weeks (n=161). 625 
Outcome Remission 
12 weeks 
 n (%) 
Reliable 
improve 
12 weeks 
 n (%) 
Recovery 
12 weeks  
n (%) 
Remission 
24 weeks 
n (%) 
Reliable 
improve 
24 weeks 
n (%) 
Recovery 
24 weeks 
n (%) 
GAD-7 
Overall, n=161 
No CBT, n=81 
 
72 (44.7) 
49 (60.5) 
 
102 (63.4) 
  67 (82.7) 
 
72 (44.7) 
49 (60.5) 
 
77 (47.8) 
53 (65.4) 
 
105 (65.2) 
  70 (86.4) 
 
77 (47.8) 
53 (65.4) 
PHQ-9 
Overall, n=161 
 
73 (45.3) 
 
 76 (47.2) 
 
61 (37.9) 
 
82 (50.9) 
 
80 (49.7) 
 
67 (41.6) 
GAD-7 and PHQ-9 
Overall, n=161 
 
62 (38.5) 
 
75 (46.6) 
 
54 (37.5) 
 
69 (42.9) 
 
75 (46.6) 
 
59 (36.5) 
AIS 
Overall, n=161 
 
39 (24.2) 
 
53 (32.9) 
 
37 (23.0) 
 
45 (28.0) 
 
60 (37.3) 
 
43 (26.7) 
 Normal 
Function 
12 weeks 
n (%) 
Functional 
recovery 
12 weeks 
n (%) 
 Normal 
Function 
24 weeks 
n (%) 
Functional 
recovery 
24 weeks 
n (%) 
 
WASA 
Overall, n=161 
 
28 (17.4) 
 
43 (26.7) 
  
29 (18.0) 
 
48 (29.8 
 
Outcome  Baseline 4 weeks 6 weeks 8 weeks 12 weeks 24 weeks 
GAD-71 15.77 (3.21)  10.14 (4.86) 9.73 (4.89) 9.34 (4.58) 8.92 (5.42) 8.99 (6.18) 
PHQ-92 16.07 (4.94) 11.22 (6.09)  10.38 (5.91) 10.04 (6.46) 8.91 (5.78)  10.42 (6.97) 
AIS3 12.91 (4.82) 10.27 (5.27) 10.18 (5.20) 9.72 (5.16) 8.81 (4.86) 7.94 (4.62) 
WSAS4 20.81 (7.74) 18.27 (8.89)  16.95 (9.56) 15.94 (9.22) 14.89 (9.99) 15.98 (9.18) 
EQ-5D-5L5 51.61 (19.00) 57.90 (20.15) 61.00 (20.47) 62.99 (21.08) 64.80 (21.72) 62.50 (22.97) 
1 Effect of treatment over time significant F =88.12, df1=5.0/df2=156.0, p < .001, partial Eta square = 0.74 (large); within 626 
subjects effect over time significant F=72.02, df1=3.7/df2=563.74, p < .001, partial Eta square = 0.31 (medium) 627 
2 Effect of treatment over time significant F=28.38, df1=5.0/df2=156.0, p < .001, partial Eta square = 0.48 (medium); within 628 
subjects effect over time significant F=42.89, df1=3.9/df=559.01, p < .001, partial Eta square = 0.21 (small) 629 
3 Effect of treatment over time significant F=40.85, df1=5.0/df2=156.0, p < .001, partial Eta square = 0.57 (large); within 630 
subjects effect over time significant F=42.69, df1=3.8/df=542.9, p < .001, partial Eta square = 0.21 (medium) 631 
4 Effect of treatment over time significant F=17.18, df1=5.0/df2=156.0, p < .001, partial Eta square = 0.36 (medium); within 632 
subjects effect over time significant F=17.35, df1=3.5/df=557.45, p < .001, partial Eta square = 0.10 (small) 633 
5 Effect of treatment over time not significant F=16.11, df1=5.0/df2=156.0, p < .001, partial Eta square = 0.34 (medium); 634 
within subjects effect over time significant F=13.94, df1=4.1/df2=651.3, p < .001, partial Eta square = 0.08 (small) 635 
 636 
  637 
638 
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Table 4: Costs and responses of Alpha-Stim CES in relation to the eight session standard care 639 
model of CBT 640 
 
 
 
      
 Deterministic Probabilistic Distribution Alpha Beta N int N control 
Cost of 
Individual CBT 
 
£887.68 
 
£923.64 
 Gamma 
         
£        
887.68  
 1    
Probability of 
Response to 
Individual CBT 
 54.2% 56% Beta 199.46 168.54 368 679 
Patients per 
Alpha-Stim CES 
lifetime 
 5.00 5.41 Gamma 5 1     
Per patient cost 
of Alpha-Stim 
CES £70.00 £64.75 Calculated         
Probability of 
Response to 
Alpha-Stim CES 
 47% 39% Beta 45 55     
 
Expected Lower Upper Expected Lower Upper 
 
Cost 95% CI 95% CI Responses 95% CI 95% CI 
iCBT only £1,294,233 £1,198,677 £1,392,923 701.68 650.29 751.85 
AlphaStim   £753,355 £651,653 £981,087 889.24 860.29 907.14 
Net  -£540,878    -£648,692 -£327,117 187.56 141.03 227.82 
 641 
